Saturday 17 October 2026
Export AYTU’s income statement to Excel — free account
Aytu BioPharma, Inc.
AYTU Healthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.
2.04
0.03
+1.49%
Follow AYTU
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 3 | 5 | 3 | 3 | 3 | 5 | 4 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(4.04) | (3.20) | (3.18) | (2.69) | (4.76) | (1.05) | (0.34) | (5.01) | (7.57) | (4.78) |
P/S ratio |
0.46 | 0.21 | 0.24 | 0.05 | 0.21 | 1.28 | 2.32 | 2.05 | 0.94 | 33.70 |
Altman Z″-Score (non-manufacturers) |
(10.35) | (8.14) | (8.62) | (7.58) | (11.88) | (2.65) | 0.23 | (11.08) | (14.82) | (23.90) |
P/FCF ratio |
8.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(3.48) | (2.67) | (3.06) | (2.72) | (5.46) | (0.57) | 0.15 | (3.01) | (0.96) | (3.26) |
P/Operating CF |
6.01 | 4.88 | (20.03) | 0.57 | (2.86) | (13.37) | (8.27) | (4.31) | (0.76) | (33.21) |
P/B ratio |
0.75 | 0.72 | 0.57 | 0.14 | 0.46 | 0.61 | 0.68 | 2.11 | 0.26 | 27.14 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.55 | 0.00 | 1.67 | 0.00 |
EV/Sales |
0.30 | 0.07 | 0.17 | (0.01) | 0.20 | 0.90 | 1.10 | 1.20 | (1.00) | 33.43 |
EV/EBITDA |
0.00 | 0.00 | 1.90 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 |
EV/Operating CF |
5.25 | (2.35) | (7.86) | 0.25 | (0.66) | (2.26) | (1.07) | (0.64) | 0.23 | (7.79) |
EV/FCF |
5.32 | (3.04) | (0.97) | 0.07 | (0.45) | (1.47) | (0.76) | (0.61) | 0.22 | (7.72) |
Quick Ratio |
0.90 | 0.98 | 0.70 | 0.75 | 0.64 | 0.71 | 1.88 | 2.43 | 2.27 | 0.39 |
Current Ratio |
1.13 | 1.26 | 0.99 | 1.03 | 0.93 | 0.96 | 2.62 | 2.87 | 2.79 | 0.84 |
Net Debt/EBITDA |
2.17 | 3.90 | (0.85) | 0.86 | 0.05 | 0.68 | 2.27 | 0.80 | 0.42 | 0.06 |
Debt/Assets |
16.22% | 17.57% | 12.81% | 11.99% | 13.22% | 9.33% | 9.46% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.48 | 1.15 | 0.55 | 0.42 | 0.41 | 0.18 | 0.15 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.50 | 0.55 | 0.51 | 0.78 | 0.48 | 0.31 | 0.29 | 0.26 | 0.20 | 0.16 |
Operating CF/Net income |
(0.23) | 0.14 | 0.09 | 0.30 | 0.27 | 0.45 | 2.08 | 0.51 | 1.56 | 0.61 |
Capex/Depreciation |
(0.01) | 0.08 | (0.04) | 0.00 | 0.00 | (0.11) | (0.94) | (0.21) | (0.18) | (0.02) |
Interest Coverage |
(4.39) | (2.11) | (0.31) | (3.44) | — | — | (8.11) | (31.46) | (26.29) | (7.94) |
| (52.55%) | (58.10%) | (47.24%) | (40.76%) | (119.62%) | (50.12%) | (26.68%) | (264.55%) | (116.94%) | (319.60%) | |
| (12.44%) | (11.20%) | (12.45%) | (12.44%) | (53.95%) | (27.83%) | (14.49%) | (97.28%) | (56.51%) | (114.43%) | |
ROIC |
(19.99%) | (49.77%) | (4.35%) | (32.58%) | (159.24%) | (32.72%) | (21.59%) | 0.00% | (195.07%) | (402.85%) |
Return on Tangible Assets |
(190.36%) | (81.47%) | (4,450.56%) | (439.57%) | 7,310.42% | (6,227.46%) | (29.03%) | (264.34%) | (161.86%) | (34,416.36%) |
Average Days of Receivables |
144.42 | 171.31 | 131.74 | 98.34 | 81.98 | 156.70 | 74.41 | 86.80 | 57.72 | 59.82 |
Research and Development Expense of Revenue |
0.00% | 2.00% | 4.25% | 3.81% | 13.10% | 8.57% | 6.23% | 8.05% | 4.58% | 41.84% |
Selling, General and Administrative Expense of Revenue |
74.07% | 57.67% | 64.49% | 65.25% | 72.29% | 85.03% | 112.41% | 262.82% | 484.48% | 546.55% |
Intangible Assets out of Total Assets |
0.39 | 0.34 | 0.44 | 0.43 | 0.51 | 0.57 | 0.50 | 0.55 | 0.54 | 0.75 |
Share Based Compensation of Revenue |
1.20% | 0.87% | 3.64% | 5.63% | 6.90% | 5.45% | 3.90% | 14.12% | 16.31% | 93.50% |
Graham Net Nets |
(0.30) | (1.90) | (1.80) | (4.87) | (1.65) | (0.27) | 0.27 | (0.81) | 0.53 | (0.07) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(63.72%) | (87.16%) | (100.35%) | (309.28%) | (552.17%) | (70.50%) | (20.88%) | (233.33%) | (295.13%) | (418.31%) |
Free Cash Flow Yield |
12.21% | (10.93%) | (71.33%) | (358.72%) | (211.30%) | (47.68%) | (62.44%) | (96.10%) | (479.99%) | (12.84%) |
Revenue per Share |
4.67 | 10.57 | 11.77 | 32.16 | 65.76 | 78.38 | 122.27 | 187.70 | 1,109.12 | 1,400.70 |
Operating CF per Share |
0.27 | (0.31) | (0.25) | (1.54) | (19.61) | (31.01) | (125.55) | (354.65) | (4,830.39) | (6,012.91) |
Capex per Share |
0.00 | 0.07 | (0.06) | 0.00 | 0.00 | (2.80) | (25.88) | (14.35) | (143.85) | (48.52) |
Free Cash Flow per Share |
0.26 | (0.24) | (0.31) | (1.54) | (19.61) | (33.80) | (151.43) | (369.01) | (4,974.24) | (6,061.43) |
Cash per Share |
2.14 | 4.93 | 3.61 | 6.88 | 13.17 | 59.59 | 213.86 | 289.59 | 2,155.30 | 381.52 |
Shareholders Equity per Share |
2.86 | 3.02 | 5.00 | 11.78 | 30.14 | 164.28 | 420.42 | 181.74 | 4,068.03 | 1,739.04 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.86 | 3.02 | 5.00 | 11.78 | 30.14 | 164.28 | 420.42 | 181.74 | 4,068.03 | 1,739.04 |
Free Cash Flow |
3.25 | (1.50) | (1.72) | (5.13) | (28.82) | (28.30) | (34.22) | (14.39) | (16.41) | (13.94) |
Working Capital |
7.10 | 16.12 | (0.34) | 2.06 | (4.51) | (4.20) | 46.66 | 10.06 | 6.08 | (0.58) |
Capital Expenditures |
(0.03) | 0.44 | (0.33) | — | — | (2.34) | (5.85) | (0.56) | (0.47) | (0.11) |
Net Current Asset Value |
(7.97) | (26.03) | (28.49) | (26.03) | (33.39) | (22.87) | 17.14 | (12.20) | 1.83 | (7.97) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.00 |
Capex to Sales |
0.00 | (0.01) | 0.01 | 0.00 | 0.00 | 0.04 | 0.21 | 0.08 | 0.13 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
10.50 | 10.31 | 10.57 | 5.16 | 28.26 | 4.28 | 24.12 | 13.39 | 11.85 | 7.26 |
Cash ROIC |
4.14% | (2.09%) | (2.73%) | (6.52%) | (35.21%) | (13.34%) | (21.68%) | (78.29%) | (79.93%) | (285.84%) |
Accounts Receivable Turnover |
2.13 | 2.43 | 2.48 | 4.24 | 3.88 | 3.88 | 7.49 | 6.31 | 6.61 | 9.33 |
Accounts Payable Turnover |
1.90 | 1.97 | 1.36 | 3.33 | 2.94 | 2.36 | 1.20 | 1.04 | 0.94 | 0.62 |
Inventory Turnover |
2.27 | 1.74 | 1.34 | 3.57 | 3.27 | 2.77 | 1.45 | 1.58 | 1.55 | 1.54 |
Average Days of Payables |
198.47 | 188.28 | 233.41 | 120.67 | 90.35 | 192.91 | 513.05 | 353.65 | 377.32 | 571.78 |
Days of Inventory on Hand |
120.66 | 203.08 | 274.75 | 107.40 | 89.21 | 163.70 | 440.72 | 238.71 | 238.35 | 337.91 |
Average Receivables |
26.97 | 27.34 | 26.23 | 25.32 | 24.94 | 16.90 | 3.69 | 1.16 | 0.55 | 0.35 |
Average Payables |
10.94 | 10.46 | 11.90 | 12.23 | 15.12 | 15.45 | 6.89 | 2.13 | 2.17 | 2.27 |
Average Inventory |
9.15 | 11.79 | 12.07 | 11.42 | 13.59 | 13.17 | 5.72 | 1.39 | 1.33 | 0.92 |
Average Assets |
114.59 | 121.14 | 127.28 | 137.04 | 201.65 | 209.48 | 94.01 | 27.89 | 18.03 | 19.67 |
Average Common Equity |
27.12 | 23.34 | 33.54 | 41.83 | 90.94 | 116.29 | 51.05 | 10.26 | 8.71 | 7.04 |
Columns are period end dates · fundamentals updated 2 Oct 2026